NACC

Directors Session Panel


Sarah Biber, PhD, NACC Program Director Monday, May 1, 2023 ADRC Spring Meeting





ADRD-Disease Modifying Drugs

Form A4a: ADRD-Specific Treatments



End date

(month/year

treatment

provided?

Start date

(month/year

which group was the

participant?

Specific treatment

and/or trial

Primary Drug Target

(check all that app


Advancing the ADRD Field

- A4a Captures information on any ADRD drugs that have been administered in the person's life (in clinical care or in a clinical trial)
- Observational "phase 4 trial" UDS infrastructure is in place for longitudinal tracking
- N.B. Dosage information is not captured



ADRD-Disease Modifying Drugs

Form A4a: ADRD-Specific Treatments




Advancing the ADRD Field

- Opportunities to build interoperability with other ADRD studies
 - Via co-enrollment with UDS
 - Via building interoperability





NACC's New Multimodal, Cloud-based, Data Platform Makes it Easier to Build Interoperability with Other Studies







NACC Infrastructure to Track Individual Data

Access to Rich Multimodal Data for Treated and Untreated Participants

This is an opportunity to study the impact of disease modifying drugs on data and biomarkers found within the NACC Data Platform





Genetic and genomic





Imaging (MRI/PET)



Neuropathology

—	
÷	
-	

Biomarker

Digital biomarker

c	
	Z
ਰ =//	
$-\nu$	

Neurocognitive tests



Electronic Health Record (EHR)









Thank you!